» Articles » PMID: 38067243

Unexplained Causes of Glioma-Associated Epilepsies: A Review of Theories and an Area for Research

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Dec 9
PMID 38067243
Authors
Affiliations
Soon will be listed here.
Abstract

Approximately 30% of glioma patients are able to survive beyond one year postdiagnosis. And this short time is often overshadowed by glioma-associated epilepsy. This condition severely impairs the patient's quality of life and causes great suffering. The genetic, molecular and cellular mechanisms underlying tumour development and epileptogenesis remain incompletely understood, leading to numerous unanswered questions. The various types of gliomas, namely glioblastoma, astrocytoma and oligodendroglioma, demonstrate distinct seizure susceptibility and disease progression patterns. Patterns have been identified in the presence of IDH mutations and epilepsy, with tumour location in cortical regions, particularly the frontal lobe, showing a more frequent association with seizures. Altered expression of TP53, MGMT and VIM is frequently detected in tumour cells from individuals with epilepsy associated with glioma. However, understanding the pathogenesis of these modifications poses a challenge. Moreover, hypoxic effects induced by glioma and associated with the HIF-1a factor may have a significant impact on epileptogenesis, potentially resulting in epileptiform activity within neuronal networks. We additionally hypothesise about how the tumour may affect the functioning of neuronal ion channels and contribute to disruptions in the blood-brain barrier resulting in spontaneous depolarisations.

Citing Articles

Impact of levetiracetam use in glioblastoma: an individual patient-level meta-analysis assessing overall survival.

Vychopen M, Guresir A, Basaran A, Guresir E, Wach J Neurosurg Rev. 2024; 47(1):897.

PMID: 39653818 PMC: 11628436. DOI: 10.1007/s10143-024-03137-x.


Combined Statistical Analysis of Glioblastoma Outcomes-A Neurosurgical Single-Institution Retrospective Study.

Tataranu L, Staicu G, Dricu A, Turliuc S, Paunescu D, Kamel A Medicina (Kaunas). 2024; 60(8).

PMID: 39202515 PMC: 11356569. DOI: 10.3390/medicina60081234.


A Novel N-Ethyl-N-nitrosourea-Induced Mouse Mutant with Audiogenic Epilepsy.

Varlamova E, Borisova E, Evstratova Y, Newman A, Kuldaeva V, Gavrish M Int J Mol Sci. 2023; 24(23).

PMID: 38069426 PMC: 10707124. DOI: 10.3390/ijms242317104.

References
1.
Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P . Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Biomed Pharmacother. 2023; 158:114204. DOI: 10.1016/j.biopha.2022.114204. View

2.
Dong Z, Min F, Zhang S, Zhang H, Zeng T . EGR1-Driven METTL3 Activation Curtails VIM-Mediated Neuron Injury in Epilepsy. Neurochem Res. 2023; 48(11):3349-3362. DOI: 10.1007/s11064-023-03950-8. View

3.
Andrews J, Wozny T, Yue J, Wang D . Improved psychotic symptoms following resection of amygdalar low-grade glioma: illustrative case. J Neurosurg Case Lessons. 2022; 4(22). PMC: 9705519. DOI: 10.3171/CASE22362. View

4.
Prakash O, Lukiw W, Peruzzi F, Reiss K, Musto A . Gliomas and seizures. Med Hypotheses. 2012; 79(5):622-6. PMC: 5736012. DOI: 10.1016/j.mehy.2012.07.037. View

5.
Mendes N, Pansani A, Carmanhaes E, Tange P, Meireles J, Ochikubo M . The Blood-Brain Barrier Breakdown During Acute Phase of the Pilocarpine Model of Epilepsy Is Dynamic and Time-Dependent. Front Neurol. 2019; 10:382. PMC: 6477033. DOI: 10.3389/fneur.2019.00382. View